Dr. Jon Inglefield received his Ph.D. from University of Rochester School of Medicine and Dentistry and, in 1997, completed a postdoctoral fellowship at Duke University Medical Center. He has held several roles in the field of immunology and toxicology. At the Environmental Protection Agency, he performed cellular toxicology work. He then moved to 3M Co.'s Pharmaceuticals Division, where he focused on in vitro toxicology and immunology. He later worked at Meso Scale Diagnostics, specializing in immunoassay development. Prior to his current position, he was involved in the clinical development of biodefense immune products at Emergent BioSolutions.
Since 2018, he has led an immunological analysis group at Frederick National Laboratory. In this role, he provides services on assay development and delivery of assay data. The analyses performed by his team have spanned small-molecule, large-molecule, cell therapy, and adenoviral vector approaches in the field of immuno-oncology. The team utilizes various immunoassays, imaging, and flow cytometry techniques in their studies. His interest continues to be in testing samples from clinical trials that focus on cytokine responses of immune therapies and in assessing T cells as correlates of immunogenicity responses in humans.
